A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 [vandetanib] in Combination With Docetaxel (Taxotere) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).

Trial Profile

A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 [vandetanib] in Combination With Docetaxel (Taxotere) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Docetaxel (Primary) ; Vandetanib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 08 Apr 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.com.
    • 06 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top